Episode Highlights
0:30 Introduction
0:48 Background into UBX1325 and BEHOLD
2:49 BEHOLD 48-week results
6:05 Next steps
6:56 Conclusion
New Insight: Phase 2 BEHOLD Study and UBX1325 for DME, Live at AAO 2023
On the floor at AAO 2023, host Veeral Sheth, MD, discusses UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.
On the floor at AAO 2023, host Veeral Sheth, MD, and producer Connor Iapoce discuss UBX1325 for patients with diabetic macular edema (DME), based on the 48-week results from the phase 2 BEHOLD study.
Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify, Apple Podcasts, and YouTube. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.
Keep an eye out for more from New Insight!
Related Videos
Related Content
